Fig. 4. CH25H expression in DCs acts to limit the lysosomal degradation otherwise induced by factors of tumor microenvironment.

a Quantitative analysis of DQ-OVA fluorescence in human CD14⁺ monocytes pretreated with PGE₂ (10 ng/mL), VEGF (20 ng/mL) or TCM from A549 cells (75%, v/v) for 24 h with or without the treatment of 25HC (4 µM) or DC661 (100 nM). n = 4 biologically independent samples. b Quantitative analysis of DQ-OVA fluorescence in bone marrow derived DCs pretreated with PGE₂ (10 ng/mL), VEGF (20 ng/mL) or TCM from LLC cells (75%, v/v) for 24 h with or without the treatment of 25HC (4 µM) or DC661 (100 nM). n = 4 biologically independent samples. c Representative histogram and quantitative analysis of DQ-OVA fluorescence in total DCs (CD45⁺CD11c⁺MHC II⁺) from naïve lungs or LLC tumor bearing lungs (i.v., 1 × 10⁶ cells/mouse, isolated 2 weeks after inoculation). Ctrl—DCs from LLC lung incubated without DQ-OVA substrate. n = 4 mice per group. d Representative histogram and quantitative analysis of DQ-OVA fluorescence in migratory DCs (CD45⁺ CD103⁺CD11b^-) from naïve lungs or LLC tumor bearing lungs (i.v., 1 × 10⁶ cells/mouse, isolated 2 weeks after inoculation). Ctrl—DCs from LLC lung incubated without DQ-OVA substrate. n = 4 mice per group. Data presented as mean ± SEM. Statistical analysis was performed using 1-way ANOVA with Tukey’s multiple-comparison test (A and B) test or 2-tailed Students’ t-test (C and D). n.s., not significant. Source data are provided as a Source Data file.